Catalyst Pharmaceutical Partners has posted positive results from a study jointly funded with, and conducted by, BioMarin Pharmaceuticals to assess the cardiac safety of Firdapse tablets (amifampridine also known as 3,4-DAP). Firdapse is approved in the EU, where it is marketed by BioMarin. Firdapse is currently in Phase III development in the U.S. for Lambert-Eaton Myasthenic Syndrome (LEMS) by Catalyst. The study met the pre-specified primary endpoint, demonstrating that at and above therapeu...